628332-15-0

Usage

Uses

Used in Pharmaceutical Industry:
6-(TRIFLUOROMETHYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical and biological properties. Its incorporation into drug molecules can potentially enhance their therapeutic effects and pharmacological profiles.
Used in Agrochemical Industry:
In the agrochemical industry, 6-(TRIFLUOROMETHYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE serves as a key component in the development of new agrochemicals. Its unique properties can contribute to the creation of more effective and targeted pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
6-(TRIFLUOROMETHYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE is used as a reagent in organic synthesis, where its versatility and reactivity are leveraged to develop new organic reactions. This can lead to the discovery of novel compounds with potential applications in various fields.
Used in Metal-Catalyzed Reactions:
As a ligand in metal-catalyzed reactions, 6-(TRIFLUOROMETHYL)-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE plays a crucial role in facilitating specific chemical transformations. Its presence can enhance the efficiency and selectivity of these reactions, enabling the synthesis of complex molecules with greater ease.

Upstream product

• 383-63-1 ethyl trifluoroacetate, 
• 123-25-1 succinic acid diethyl ester 
• 22581-31-3 methyl 5,5,5-trifluoro-4-oxopentanoate 
• 87341-14-8 tert-butyl 3-[5-oxo-4-(propan-2-yl)-2-(trifluoromethyl)-2,5-dihydro-1,3-oxazol-2-yl]propanoate 

Downstream Products

• 258506-68-2 3-chloro-6-(trifluormethyl)pyridazine 
• 174607-36-4 6-(trifluoromethyl)pyridazin-3(2H)-one 

Relevant academic research and scientific papers

Synthesis of perfluoroalkyl-substituted γ-lactones and 4,5-dihydropyridazin-3(2H)-ones via donor-acceptor cyclopropanes

Rh2(OAc)4-Catalyzed decomposition of diazo esters in the presence of perfluoroalkyl- or perfluoroaryl-substituted silyl enol ethers smoothly provided the corresponding alkyl 2-siloxycyclopropanecarboxylates in very good yields. The generated donor-acceptor cyclopropanes are equivalents of γ-oxo esters, which we demonstrated by their one-pot transformations to yield fluorine-containing heterocycles. A reductive procedure selectively afforded perfluoroalkyl-substituted γ-hydroxy esters or γ-lactones. The treatment of the donor-acceptor cyclopropanes with hydrazine or phenylhydrazine afforded a series of perfluoroalkyl- and perfluoroaryl- substituted 4,5-dihydropyridazin-3(2H)-ones. Copyright

OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF

The present application relates to novel carboxylic acid derivatives having an oxo-substituted azaheterocyclic partial structure, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

Concise synthesis of ω-fluoroalkylated ketoesters. A building block for the synthesis of six-, seven-, and eight-membered fluoroalkyl substituted 1,2-diaza-3-one heterocycles

A concise and general synthetic route toward the small and medium-sized fluoroalkyl substituted 1,2-diaza-3-one heterocyclic ring skeletons via a sequential reaction of condensation and ring-closure reaction of ω-fluoroalkylated ketoesters 4 with hydrazin

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.

1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY

A compound represented by the formula (1) wherein ring A is a ring optionally having 1 to 3 substituents; ring B is a 1,2-azole ring which may further have 1 to 3 substituents; Xa, Xb and Xc are the same or different and each is a bond, - O -, - S - and the like; Ya is a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; Yb and Yc are the same or different and each is a bond or a divalent aliphatic hydrocarbon residue having 1 to 20 carbon atoms; ring C is a monocyclic aromatic ring which may further have 1 to 3 substituents; and R represents -OR4 (R4 is hydrogen atom or optionally substituted hydrocarbon group) and the like, or a salt thereof or a prodrug thereof is useful as an agent for the prophylaxis or treatment of diabetes and the like.